TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace and defense, and industrial markets worldwide.
FAIL · Does not pass the screen
39.60 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price39.60 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans to puts (put/call 35.00)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 39.60 against the desk's fair-value range, base estimate 32.21, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 35.00, read 2026-10-24
Ethical does not pass the values gate
Price39.60 USD
Fair value32.21
Ethical score70.0/100
Our investment reviews on this name
2026-10-22Read Accumulation38.43+3.0% to today ✓Markdown gives way to Accumulation
2026-10-15Read Markdown38.15+3.8% to today Accumulation gives way to Markdown first Markdown read since September
2026-10-02Read Accumulation38.08+4.0% to today ✓Markdown gives way to Accumulation
2026-08-15Read Markdown39.24+0.9% to today Markup gives way to Markdown after a 5% slide in 6 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
TriMas Corporation holds its Accumulation at $39.60. The statistical read favours the buyers, held for 2 days.
As held on the ledger · 2026-10-23
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 2 days
Price at the screen
$39.60
Valuation
16.22 trailing · 18.74 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.61
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.01%
Below 33%
Interest-bearing debt is 34.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.51%
Below 49%
Money owed to the company is 9.5% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
TriMas's business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TRS's ethical verdict changes
Today TRS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 18.7% above the base estimate.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TRS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$39.60-0.8%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$39.90+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$39.90+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$39.90+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$39.90+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$39.90+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$39.90+3.8%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown · changed$38.15+0.2%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (2 analysts) rates it none, with a mean price target of $45.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
